BNB Plus Corp (BNBX) Fiyat

BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. The company is headquartered in Stony Brook, New York and currently employs 26 full-time employees. The company went IPO on 2001-08-24. Its segments include digital asset treasury, therapeutic deoxyribonucleic acid (DNA) production services, DNA tagging and security products and services. Its digital asset treasury segment is engaged in managing digital assets. Its therapeutic DNA production services segment is engaged in nucleic-acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP and LineaIVT. Its DNA tagging and security products and services segment is engaged in the manufacture and detection of DNA for industrial supply chains and security services. Its subsidiary LineaRx, Inc., is engaged in commercializing nucleic acid production solutions for the biopharmaceutical and diagnostics markets.